BCT.TO - BriaCell Therapeutics Corp.
| Previous Close | 8.40 |
| Open | 8.32 |
| Bid | 8.23 x N/A |
| Ask | 8.34 x N/A |
| Day's Range | 8.19 - 8.40 |
| 52 Week Range | 5.77 - 10.91 |
| Volume | |
| Avg. Volume | 10,196 |
| Market Cap | 130.888M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- Baystreet
Stocks in play: BriaCell Therapeutics Corp.
Announced that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics ...
GlobeNewswireBriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp. (“SpinCo”), a wholly-owned subsidiary of the Company (the “Ar
- GlobeNewswire
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share
PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC (“Prevail Partners”) in the Company (the “Investment”), in accordance with a stock purchase agreement (the “Agre
- GlobeNewswire
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.
Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP.Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell’s upcoming pivotal study, expected to commence in 2023. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”)
- GlobeNewswire
BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR
15 of 18 patients remain alive of those recruited since the study reopened in 2021.Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment.The Bria-IMT™ combination regimen activated the immune system even in anergic patients with very weak immune systems.Continued positive clinical data suggests more meaningful survival and clinical benefits in advanced metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbi
Simply Wall St.BriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held
SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer.SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announc
- GlobeNewswire
BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida. The available abstract titles and
- Simply Wall St.
A BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last year
From what we can see, insiders were net buyers in BriaCell Therapeutics Corp.'s ( TSE:BCT ) during the past 12 months...
- GlobeNewswire
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits.Remains well tolerated with no dose limiting toxicities.Primary endpoint in pending pivotal trial will be survival, as agreed by the FDA.9 additional patients have been screened/enrolled in the study, incremental to the 12 patients announced in December 2022. PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”
- Simply Wall St.
BriaCell Therapeutics Corp. (TSE:BCT) most popular amongst individual investors who own 59%, insiders hold 14%
To get a sense of who is truly in control of BriaCell Therapeutics Corp. ( TSE:BCT ), it is important to understand the...
- GlobeNewswire
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2022 held on February 9, 2023 (the “Meeting”). A total of 6,663,370 common share
- GlobeNewswire
BriaCell CEO Letter to Shareholders
Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization.Pivotal study's primary endpoint to be linked to survival improvement. PHILADELPHIA and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX
- GlobeNewswire
BriaCell to Investigate Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes that certain individuals and/or companies may have engaged in manipulative and/or suspecte
- GlobeNewswire
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast cancer.After reviewing BriaCell’s Fast Track designated Phase I/IIa data, the FDA has agreed on the primary end point, the essential elements of the pivotal registration study design, and type of patients to be included.Registration study success could lead to a Biologics License Applic
- GlobeNewswire
BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with FDA guidance.Two additional clinical sites are now active in Phase II Bria-IMT™ study to broaden patient access: Carle Cancer Institute in Urbana, Illinois and the American Oncology Netwo
- GlobeNewswire
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.“Better quality of life” and “less pain” reported by many gravely ill advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen. Notably, many patients remained in our study longer than other prior therapies, suggesting excellent to
News DirectBriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
By Faith Ashmore, Benzinga
Business WireIPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA, November 30, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology c
GlobeNewswireBriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com
Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT). AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the posi
GlobeNewswireBriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The regimen remains well tolerated as recently reported in Phase I evaluation. 70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.Prior to enrollment, the 12 patients in the cohort had already been unsuccessfull
- GlobeNewswire
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer. The combination treatment showed a favorable safety profile in 12 patients. Phase II efficacy portion of the study, under FDA’s fast track designation, now underway with survival data and clinical benefit being compiled. PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasda
- Simply Wall St.
Here's Why We're Not Too Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer. “We are thri
- GlobeNewswire
BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in Sa